sarcoidosis epidemiology forecast insight

DelveInsight’s ‘Sarcoidosis – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the historical and forecasted epidemiology of sarcoidosis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Sarcoidosis: Disease Understanding

Sarcoidosis Overview

Sarcoidosis is a multisystem granulomatous inflammatory disease, with the lungs and intrathoracic lymph nodes being the most frequently affected sites. Patients typically experience fatigue, weakness, and dyspnea. Furthermore, respiratory muscle weakness, secondary to granulomatous inflammation, is associated with dyspnea and decreased quality of life (QOL).

The presentation of sarcoidosis varies considerably from mild, acute self-limiting disease to chronic disease involving several organs and causing severe symptoms and functional impairment. The condition is staged from I (least severe) to III (most severe): 55–90% of patients presenting with stage I disease, 40–70% of patients with stage II disease,  and 10–20% of patients with stage III  disease. Patients with advanced sarcoidosis may develop pulmonary hypertension for a variety of reasons. Sarcoidosis-associated pulmonary hypertension (SAPH) is a significant complication of sarcoidosis and is associated with significant morbidity and mortality. Over the past few years, increased recognition has led to more frequent identification of SAPH patients.

The diagnosis of sarcoidosis relies on the presence of noncaseating granuloma on histopathologic examination, compatible clinical presentation, and exclusion of other causes of granulomatous inflammation. There are no universally accepted measures to determine if each diagnostic criterion has been satisfied; therefore, the diagnosis of sarcoidosis is never entirely secure.

Most patients with sarcoidosis do not require treatment and often make a full recovery. However, around a third of patients have more serious diseases involving different organs and require therapies that suppress the immune system. The goals of sarcoidosis management are to prevent or control organ damage, relieve symptoms, and improve the patient’s quality of life. For patients with extrapulmonary involvement, a multidisciplinary approach may be required.

Glucocorticoids (GC) are the first-line therapy, whereas glucocorticoid-sparing agents and biologic agents are used in refractory/recurrent cases. Methotrexate is the most commonly used corticosteroid-sparing agent for corticosteroid-resistant disease or corticosteroid-intolerant patients. Other second-line agents include hydroxychloroquine, leflunomide, azathioprine, mycophenolate, and others. Third-line agents include infliximab, adalimumab, and others. Other treatment considerations include cyclophosphamide, rituximab, adrenocorticotropic hormone, and pentoxifylline. Regardless of whether treatment is started, the clinician needs to organize regular follow-up to monitor remissions, flares, progression, complications, toxicity, and relapses to promptly adjust the drugs used.

Sarcoidosis: Epidemiology

The Sarcoidosis epidemiology division provides insights about the historical and current patient pool, along with the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted sarcoidosis epidemiology segmented as the prevalent cases of sarcoidosis, gender-specific cases of sarcoidosis, and age-specific cases of sarcoidosis. The report includes the prevalent scenario sarcoidosis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country-wise Sarcoidosis Epidemiology

The epidemiology segment also provides the Sarcoidosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• The total prevalent population of sarcoidosis in the 7MM countries was 249,250 cases in 2020.
• As per the estimates, the United States had the highest prevalent sarcoidosis population in 2020. Among the EU5 countries, Germany had the highest prevalent population of sarcoidosis with 29,708 cases, followed by Italy in 2020. On the other hand, Spain had the lowest prevalent population of 4,091 cases in 2020.

Scope of the Report

• Sarcoidosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• Sarcoidosis Epidemiology Report and Model provide an overview of the risk factors and global trends of sarcoidosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of sarcoidosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of sarcoidosis.
• The report provides the segmentation of the sarcoidosis epidemiology by prevalent cases of sarcoidosis in the 7MM.
• The report provides the segmentation of the sarcoidosis epidemiology by gender-specific cases of sarcoidosis in the 7MM.
• The report provides the segmentation of the sarcoidosis epidemiology by age-specific cases of sarcoidosis in the 7MM.

Report Highlights

• 10-year Forecast of Sarcoidosis epidemiology
• 7MM Coverage
• Prevalent Cases of Sarcoidosis
• Gender-specific Cases of Sarcoidosis
• Age-specific Cases of Sarcoidosis

KOL Views

We interview KOLs and obtain SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM for the patient population pertaining to sarcoidosis?
• What are the key findings pertaining to the sarcoidosis epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021-2034)?
• What would be the total number of patients with sarcoidosis across the 7MM during the forecast period (2021-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021-2034)?
• At what CAGR the patient population is expected to grow in the 7MM during the forecast period (2021-2034)?
• What are the disease risk, burdens, and unmet needs of sarcoidosis?
• What are the currently available treatments for sarcoidosis?

Reasons to buy

Sarcoidosis Epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global Sarcoidosis market
• Quantify patient populations in the global Sarcoidosis market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Sarcoidosis therapeutics in each of the markets covered
• Understand the magnitude of the Sarcoidosis population by its prevalent cases.
• Understand the magnitude of the Sarcoidosis population by its gender-specific cases.
• Understand the magnitude of the Sarcoidosis population by its age-specific cases.
• The Sarcoidosis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Sarcoidosis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population